Harmonizing outcomes with revascularization and stents horizons trial l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 3

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial PowerPoint PPT Presentation


  • 108 Views
  • Uploaded on
  • Presentation posted in: General

HORIZONS Trial. Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial. HORIZONS Trial: Study Design. 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

Download Presentation

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Harmonizing outcomes with revascularization and stents horizons trial l.jpg

HORIZONS Trial

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial


Horizons trial study design l.jpg

HORIZONS Trial: Study Design

3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.

Antithrombotic Therapy

Randomized 1:1

Bivalirudin + Bail-Out IIb/IIIa Inhibitor

n=1700

UFH + IIb/IIIa Inhibitor

n=1700

Target Vessel Stenting to DES vs BMS Randomized 3:1

  • Hypothesis 1: Bivalirudin compared to UFH + routine IIb/IIIa will reduce the composite rate of death, reinfarction, TVR, stroke, and major bleeding at 30 days

Presented at TCT 2005


Slide3 l.jpg

HORIZONS Trial: Study Design

3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.

Antithrombotic Therapy

Randomized 1:1

Target Vessel Stenting

Randomized 3:1

TAXUS stent

n=2250

Bare metal Express stent

n=750

  • Hypothesis 2: Use of polymer-based slow-release paclitaxel-eluting TAXUS stent will safely reduce the 1 year rate of ischemia-driven TLR

Presented at TCT 2005


  • Login